Warfarin side effects: what 126,271 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Warfarin Sodium
Who reports
126,271 reports · 80% serious · 16,103 with death outcome · 49% female
Used for
Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.
What it is
4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one is a member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.
Boxed warning
BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ] . Perform regular monitoring of INR in all treated patients [see Dosage and Administration (2.1) ] . Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see Drug Interactions (7) ] .
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,187 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Appendicolith | 267 | 402.6 322.0–503.4ROR 403.5 · calibrated p 1e-12 ✓ | 115.7 EB05 104.5 · IC025 +6.4 3/3 methods agree | Not in label — unassessed | serious n=267 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| Anticoagulation drug level above therapeutic | 972 | 287.3 258.8–318.9ROR 289.5 · calibrated p 1e-11 ✓ | 104.4 EB05 99.0 · IC025 +6.5 3/3 methods agree | Lab value / disease marker | serious n=831 · 95% clinician | no trial arm names this drug |
| Anticoagulation drug level below therapeutic | 378 | 160.3 139.1–184.7ROR 160.8 · calibrated p 3e-9 ✓ | 81.0 EB05 74.3 · IC025 +6.0 3/3 methods agree | Lab value / disease marker | serious n=322 · 92% clinician | no trial arm names this drug |
| Sleep disorder therapy | 90 | 155.9 116.8–208.2ROR 156.0 · calibrated p 7e-9 ✓ | 78.8 EB05 66.1 · IC025 +5.5 3/3 methods agree | Reporting / coding artifact | serious n=90 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| Calciphylaxis | 729 | 110.2 100.4–121.1ROR 110.9 · calibrated p 5e-8 ✓ | 66.0 EB05 62.1 · IC025 +5.9 3/3 methods agree | Labeled — boxed warning exact term | serious n=728 · ♀ 70% (drug 49%) · 100% clinician | no trial arm names this drug |
| International normalised ratio abnormal | 1,265 | 95.2 88.9–102.1ROR 96.2 · calibrated p 2e-7 ✓ | 60.4 EB05 57.7 · IC025 +5.8 3/3 methods agree | Lab value / disease marker | serious n=931 | no trial arm names this drug |
| International normalised ratio increased | 10,358 | 93.4 91.2–95.6ROR 101.7 · calibrated p 1e-7 ✓ | 59.7 EB05 58.8 · IC025 +5.9 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 59.9 · serious PRR 44.0 | no trial arm names this drug |
| International normalised ratio decreased | 1,368 | 83.6 78.3–89.2ROR 84.5 · calibrated p 4e-7 ✓ | 55.5 EB05 53.1 · IC025 +5.7 3/3 methods agree | Lab value / disease marker | serious n=1,053 | no trial arm names this drug |
| Analgesic therapy | 100 | 80.2 63.1–101.9ROR 80.3 · calibrated p 8e-7 ✓ | 53.6 EB05 45.3 · IC025 +5.1 3/3 methods agree | Reporting / coding artifact | serious n=100 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| Drug therapy | 99 | 74.3 58.6–94.2ROR 74.4 · calibrated p 1e-6 ✓ | 50.9 EB05 43.0 · IC025 +5.0 3/3 methods agree | Reporting / coding artifact | serious n=99 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| International normalised ratio fluctuation | 595 | 65.7 59.8–72.3ROR 66.0 · calibrated p 2e-6 ✓ | 47.1 EB05 44.0 · IC025 +5.4 3/3 methods agree | Lab value / disease marker | serious n=377 | no trial arm names this drug |
| Steroid dependence | 174 | 42.6 36.1–50.3ROR 42.7 · calibrated p 4e-5 ✓ | 33.9 EB05 29.8 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=174 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| Catarrh | 159 | 36.0 30.3–42.8ROR 36.1 · calibrated p 1e-4 ✓ | 29.6 EB05 25.9 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=159 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| Prothrombin time abnormal | 108 | 30.6 24.9–37.6ROR 30.6 · calibrated p 3e-4 ✓ | 25.8 EB05 22.0 · IC025 +4.2 3/3 methods agree | Lab value / disease marker | serious n=67 | no trial arm names this drug |
| Spinal epidural haematoma | 86 | 29.7 23.6–37.4ROR 29.8 · calibrated p 3e-4 ✓ | 25.2 EB05 21.0 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=86 · ♀ 100% (drug 49%) · 100% clinician | no trial arm names this drug |
| Abdominal wall haematoma | 285 | 28.4 25.0–32.2ROR 28.4 · calibrated p 4e-4 ✓ | 24.3 EB05 22.0 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=278 · 100% clinician | no trial arm names this drug |
| Coagulation time prolonged | 228 | 28.3 24.6–32.6ROR 28.4 · calibrated p 4e-4 ✓ | 24.2 EB05 21.7 · IC025 +4.3 3/3 methods agree | Lab value / disease marker | serious n=214 · 100% clinician | no trial arm names this drug |
| Prothrombin time prolonged | 771 | 24.2 22.4–26.0ROR 24.3 · calibrated p 8e-4 ✓ | 21.2 EB05 19.9 · IC025 +4.3 3/3 methods agree | Lab value / disease marker | serious n=691 | no trial arm names this drug |
| Vascular calcification | 134 | 23.6 19.7–28.2ROR 23.6 · calibrated p 1e-3 ✓ | 20.7 EB05 17.9 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=134 | no trial arm names this drug |
| Retroperitoneal haematoma | 268 | 23.0 20.2–26.1ROR 23.0 · calibrated p 0.001 ✓ | 20.2 EB05 18.3 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=266 · 100% clinician | no trial arm names this drug |
| Coagulation test abnormal | 86 | 21.0 16.8–26.3ROR 21.0 · calibrated p 0.002 ✓ | 18.7 EB05 15.6 · IC025 +3.7 3/3 methods agree | Reporting / coding artifact | serious n=83 · ♀ 100% (drug 49%) · 100% clinician | no trial arm names this drug |
| Intra-abdominal haematoma | 135 | 20.1 16.8–24.1ROR 20.2 · calibrated p 0.002 ✓ | 18.0 EB05 15.6 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=134 · 100% clinician | no trial arm names this drug |
| Retroperitoneal haemorrhage | 261 | 19.5 17.2–22.2ROR 19.6 · calibrated p 0.002 ✓ | 17.5 EB05 15.8 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=257 · 100% clinician | no trial arm names this drug |
| Labelled drug-drug interaction medication error | 878 | 18.0 16.8–19.3ROR 18.1 · calibrated p 0.003 ✓ | 16.3 EB05 15.4 · IC025 +3.9 3/3 methods agree | Reporting / coding artifact | serious PRR 13.3 | no trial arm names this drug |
| Catheter site pruritus | 84 | 17.5 14.0–22.0ROR 17.5 · calibrated p 0.004 ✓ | 15.9 EB05 13.2 · IC025 +3.5 3/3 methods agree | Labeled (related wording) related wording | serious n=70 · ♀ 100% (drug 49%) · 100% clinician | no trial arm names this drug |
| Gastric haemorrhage | 1,081 | 17.0 16.0–18.1ROR 17.1 · calibrated p 0.004 ✓ | 15.5 EB05 14.7 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious PRR 11.1 · ♀ 10% (drug 49%) · 94% clinician | no trial arm names this drug |
| Catheter management | 84 | 17.0 13.5–21.2ROR 17.0 · calibrated p 0.005 ✓ | 15.4 EB05 12.8 · IC025 +3.5 3/3 methods agree | Reporting / coding artifact | serious n=80 · ♀ 100% (drug 49%) · 100% clinician | no trial arm names this drug |
| Cardioactive drug level increased | 121 | 16.6 13.7–20.0ROR 16.6 · calibrated p 0.005 ✓ | 15.1 EB05 12.9 · IC025 +3.5 3/3 methods agree | Lab value / disease marker | serious n=116 · 100% clinician | no trial arm names this drug |
| Burns second degree | 157 | 16.3 13.8–19.2ROR 16.3 · calibrated p 0.005 ✓ | 14.9 EB05 13.0 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=157 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| Subdural haemorrhage | 237 | 15.6 13.6–17.8ROR 15.6 · calibrated p 0.006 ✓ | 14.3 EB05 12.8 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=234 | no trial arm names this drug |
| Haematoma muscle | 101 | 15.5 12.6–19.0ROR 15.5 · calibrated p 0.007 ✓ | 14.2 EB05 12.0 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=99 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| Haemorrhage intracranial | 1,266 | 15.2 14.4–16.1ROR 15.4 · calibrated p 0.006 ✓ | 14.0 EB05 13.4 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious PRR 10.0 · 95% clinician | no trial arm names this drug |
| Blood phosphorus increased | 217 | 14.3 12.4–16.4ROR 14.3 · calibrated p 0.009 ✓ | 13.2 EB05 11.8 · IC025 +3.5 3/3 methods agree | Lab value / disease marker | serious n=215 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
| Subdural haematoma | 1,141 | 14.3 13.4–15.1ROR 14.4 · calibrated p 0.008 ✓ | 13.2 EB05 12.5 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious PRR 9.4 · 93% clinician | no trial arm names this drug |
| Catheter site discharge | 84 | 13.7 10.9–17.1ROR 13.7 · calibrated p 0.011 ✓ | 12.5 EB05 10.4 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=76 · ♀ 100% (drug 49%) | no trial arm names this drug |
| Muscle haemorrhage | 305 | 13.6 12.1–15.3ROR 13.6 · calibrated p 0.010 ✓ | 12.6 EB05 11.5 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=303 · 91% clinician | no trial arm names this drug |
| Occult blood positive | 149 | 13.3 11.3–15.8ROR 13.4 · calibrated p 0.012 ✓ | 12.3 EB05 10.7 · IC025 +3.3 3/3 methods agree | Lab value / disease marker | serious n=142 · 100% clinician | no trial arm names this drug |
| Catheter site erythema | 155 | 13.2 11.2–15.5ROR 13.2 · calibrated p 0.012 ✓ | 12.2 EB05 10.7 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=134 · ♀ 76% (drug 49%) | no trial arm names this drug |
| Peritoneal haemorrhage | 101 | 12.8 10.4–15.6ROR 12.8 · calibrated p 0.014 ✓ | 11.8 EB05 9.9 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=101 · 100% clinician | no trial arm names this drug |
| Hyperphosphataemia | 150 | 12.6 10.7–14.8ROR 12.6 · calibrated p 0.015 ✓ | 11.7 EB05 10.2 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=147 · ♀ 0% (drug 49%) · 100% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Gi bleeding | 6,738 | 6.36.2–6.5 | signal |
| Arrhythmia / qt | 4,977 | 4.44.2–4.5 | signal |
| Heart failure | 4,416 | 4.24.1–4.3 | signal |
| Venous thromboembolism | 5,081 | 4.03.9–4.1 | signal |
| Anaemia | 6,712 | 3.83.7–3.9 | signal |
| Stroke | 4,558 | 3.13.0–3.2 | signal |
| Kidney injury | 7,219 | 2.72.6–2.7 | signal |
| Hyponatraemia | 1,229 | 2.62.4–2.7 | signal |
| Fall / fracture | 5,128 | 2.32.2–2.3 | signal |
| Rhabdomyolysis / myopathy | 948 | 2.01.8–2.1 | raised |
| Serious infection | 8,871 | 1.91.9–2.0 | raised |
| Thrombocytopenia | 2,158 | 1.61.6–1.7 | raised |
| Interstitial lung disease | 923 | 1.61.5–1.7 | raised |
| Myocardial infarction | 1,742 | 1.41.4–1.5 | raised |
| Hypoglycaemia | 781 | 1.41.3–1.5 | raised |
| Liver injury | 2,028 | 1.11.1–1.2 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| International normalised ratio increased | 10,358 | 93.4 91.2–95.6ROR 101.7 · calibrated p 1e-7 ✓ | 59.7 EB05 58.8 · IC025 +5.9 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 59.9 · serious PRR 44.0 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 8,503 | 2.5 2.5–2.6ROR 2.6 · calibrated p 0.760 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 2.1 | no trial arm names this drug |
| Drug interaction | 6,363 | 6.9 6.7–7.1ROR 7.2 · calibrated p 0.091 | 6.7 EB05 6.5 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 5.4 · serious PRR 5.0 | no trial arm names this drug |
| Fatigue (tiredness) | 6,233 | 1.3 1.3–1.4ROR 1.4 · calibrated p 0.543 | 1.3 EB05 1.3 · IC025 +0.4 | Not in label — unassessed | age-adj. PRR 1.2 · serious PRR 1.3 | no trial arm names this drug |
| Nausea | 6,007 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.494 | 1.3 EB05 1.2 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.2 · serious PRR 1.3 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 5,971 | 1.5 1.5–1.6ROR 1.6 · calibrated p 0.689 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.3 · serious PRR 1.4 | no trial arm names this drug |
| Dizziness | 5,210 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.816 | 1.7 EB05 1.7 · IC025 +0.8 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.7 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 5,196 | 0.7 0.6–0.7ROR 0.6 · calibrated p 0.101 | 0.7 EB05 0.6 · IC025 -0.7 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.8 · serious PRR 0.9 | no trial arm names this drug |
| Fall | 4,853 | 2.4 2.4–2.5ROR 2.5 · calibrated p 0.812 | 2.4 EB05 2.4 · IC025 +1.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.7 · serious PRR 1.9 | no trial arm names this drug |
| Death | 4,765 | 0.9 0.9–0.9ROR 0.9 · calibrated p 0.252 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Outcome field, not a reaction boxed warning mentions mortality | age-adj. PRR 0.8 · serious PRR 0.7 | no trial arm names this drug |
| Headache | 4,729 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.485 | 1.3 EB05 1.2 · IC025 +0.3 | Not in label — unassessed | age-adj. PRR 1.3 · serious PRR 1.3 | no trial arm names this drug |
| Asthenia (weakness) | 4,403 | 2.0 1.9–2.0ROR 2.0 · calibrated p 0.939 | 1.9 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.6 · serious PRR 1.7 | no trial arm names this drug |
| Pneumonia (lung infection) | 4,155 | 2.1 2.1–2.2ROR 2.2 · calibrated p 0.957 | 2.1 EB05 2.1 · IC025 +1.0 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.7 · serious PRR 1.6 | no trial arm names this drug |
| Haemorrhage | 4,059 | 6.7 6.5–6.9ROR 6.9 · calibrated p 0.105 | 6.4 EB05 6.3 · IC025 +2.6 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 6.8 · serious PRR 5.3 | no trial arm names this drug |
| Off label use (used outside approved label) | 3,981 | 0.8 0.7–0.8ROR 0.8 · calibrated p 0.158 | 0.8 EB05 0.7 · IC025 -0.4 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.7 · serious PRR 0.8 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Appendicolith — n=267, PRR 402.6
- Steroid dependence — n=174, PRR 42.6
- Catarrh — n=159, PRR 36.0
- Spinal epidural haematoma — n=86, PRR 29.7
- Abdominal wall haematoma — n=285, PRR 28.4
- Retroperitoneal haematoma — n=268, PRR 23.0
- Intra-abdominal haematoma — n=135, PRR 20.1
- Retroperitoneal haemorrhage — n=261, PRR 19.5
- Gastric haemorrhage — n=1,081, PRR 17.0
- Burns second degree — n=157, PRR 16.3
✓ A hand-written Bradford Hill causality assessment exists for this drug: Warfarin ↔ INR increased.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Warfarin?
In FDA FAERS, the most frequently co-reported reaction terms for Warfarin are international normalised ratio increased, dyspnoea, fatigue, nausea, diarrhoea, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Warfarin have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ] . Perform regular monitoring of INR in all treated patients [see Dosage and Administration (2.1) ] . Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see Drug Interactions (7) ] .
Do FAERS signals prove that Warfarin causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 2cbcc99d-9107-4d39-a1e9-e19305de8b5d, effective 20260625; matched on
openfda.generic_name.exact:"WARFARIN" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 54678486 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,227 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
WARFARIN, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.